Bruton’s tyrosine kinase (BTK) is a crucial component of the B-cell receptor-signaling pathway that has been associated with the pathogenesis of B-cell malignancies. Ibrutinib is an oral BTK inhibitor that showed promising antitumor activity in preclinical lymphoma models. Subsequently, ibrutinib was tested in prospective clinical studies and was found to be active in various B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM).
- About Lymphoma
- What is Lymphoma?
- Symptoms of Lymphoma
- Tests, Diagnosis and Staging
- Treatments
- Aim of treatment
- Understanding Watch & Wait
- Central venous access devices
- Chemotherapy
- Radiotherapy
- Oral therapies
- Immunotherapy
- Maintenance therapy
- Steroid therapy
- Growth Factors
- Splenectomy
- Biosimilars
- Blood products
- Immunoglobulin replacement therapy
- Complementary therapy
- Pregnancy and Lymphoma
- Clinical Trials
- Side Effects of Treatment
- Pregnancy and Lymphoma
- Types of Lymphoma
- Support for You
- Healthcare Professionals
- Get Involved
- Donate